<DOC>
	<DOC>NCT01011322</DOC>
	<brief_summary>The participation in this clinical study will last approximately 21 weeks with a 1 week screening period and a 12 weeks treatment duration. If the study doctor finds, that the patients disease has significantly improved he/she will enter a treatment free follow-up period of 8 weeks. In total the study consists of 5 to 6 clinical visits (V1 - V6) and 1 telephone follow-up call.</brief_summary>
	<brief_title>A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<criteria>Men and women 18 years or older who have given written Informed Consent Patients with proven ulcerative colitis Active disease course for the last 6 weeks or longer with bloody diarrhea Patients with an inadequate response to a treatment with mesalazine or a documented intolerance to mesalazine. Infectious colitis, including cytomegalovirus or Clostridium difficile induced colitis, Crohn's disease, Colitis due to other reasons than ulcerative colitis like known diverticulitis, radiation colitis, ischemic colitis, microscopic colitis, or indeterminate colitis, Treatment with other investigational medicinal product within 3 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>